Stryker Corporation $SYK Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in Stryker Corporation (NYSE:SYK) by 6.7% during the second quarter, Holdings Channel reports. The firm owned 422,824 shares of the medical technology company’s stock after selling 30,390 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Stryker were worth $167,282,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Consolidated Portfolio Review Corp raised its position in shares of Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after buying an additional 26 shares during the period. Princeton Global Asset Management LLC increased its stake in Stryker by 16.9% during the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after acquiring an additional 26 shares during the last quarter. Sunflower Bank N.A. raised its holdings in shares of Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after purchasing an additional 27 shares during the period. Pitti Group Wealth Management LLC lifted its stake in shares of Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after purchasing an additional 27 shares in the last quarter. Finally, Sachetta LLC grew its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on SYK shares. Needham & Company LLC restated a “buy” rating and issued a $448.00 price target on shares of Stryker in a report on Friday. Evercore ISI cut their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Truist Financial increased their price target on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a report on Friday. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a research report on Friday. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $434.37.

Stryker Price Performance

SYK opened at $362.39 on Friday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The firm has a market cap of $138.59 billion, a price-to-earnings ratio of 48.00, a PEG ratio of 2.66 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a fifty day simple moving average of $371.96 and a 200 day simple moving average of $381.22.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the prior year, the company posted $2.87 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 520,500 shares of company stock valued at $184,803,065. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.